Methods to lower LDL cholesterol
Pro Research Analysisby 
Searched over 200M research papers
Statins as the Primary LDL Cholesterol-Lowering Therapy
Statins are the first-line treatment for lowering LDL cholesterol and reducing cardiovascular disease risk. They are effective, widely used, and recommended by clinical guidelines for most patients at risk of cardiovascular disease. High-potency statins can achieve significant reductions in LDL cholesterol, and their benefits have been confirmed in large clinical trials across various patient populations, including older adults Brautbar2011Luo2022Pirillo2020+1 MORE.
Nonstatin LDL Cholesterol-Lowering Medications
When statins alone are not enough or are not tolerated, several nonstatin therapies can be used:
Ezetimibe
Ezetimibe works by reducing cholesterol absorption in the intestine. It is often combined with statins to achieve further LDL cholesterol reduction, especially in patients who cannot tolerate high-intensity statins or need additional lowering Luo2022Toth2022Pirillo2020+3 MORE.
PCSK9 Inhibitors
PCSK9 inhibitors, such as evolocumab and alirocumab, are injectable drugs that significantly lower LDL cholesterol by increasing its clearance from the blood. They are particularly effective when added to statin therapy and are recommended for patients at high risk or with genetic conditions like familial hypercholesterolemia Nurmohamed2021Luo2022Toth2022+4 MORE.
Bempedoic Acid
Bempedoic acid is an oral medication that lowers LDL cholesterol by inhibiting cholesterol synthesis upstream of statins. It is a useful alternative for patients who are intolerant to statins and can be used alone or in combination with ezetimibe Nurmohamed2021Luo2022Toth2022.
Bile Acid Sequestrants, Niacin, and Fibrates
Other established nonstatin options include bile acid sequestrants, niacin, and fibrates. These agents can lower LDL cholesterol, but their use is less common due to side effects and less robust evidence for reducing cardiovascular events when added to statins Costet2010Pirillo2020Hegele2015.
Emerging and Investigational Therapies
Several new and investigational drugs are being developed to further lower LDL cholesterol, especially for patients with severe or genetic forms of high cholesterol:
- Inclisiran: A small interfering RNA that targets PCSK9, requiring only twice-yearly dosing Nurmohamed2021Luo2022.
- ANGPTL3 Inhibitors: Targeting angiopoietin-like 3 protein, these drugs are promising for patients with homozygous familial hypercholesterolemia .
- CETP Inhibitors: Cholesteryl ester transfer protein inhibitors, such as obicetrapib, are under investigation for their LDL-lowering effects Nurmohamed2021Luo2022.
- Lomitapide and Mipomersen: Used in rare cases of familial hypercholesterolemia, these drugs work independently of the LDL receptor .
Combination and Alternative Strategies
Combining moderate-intensity statins with ezetimibe or other nonstatin agents can be as effective as high-intensity statin therapy, with similar cardiovascular outcomes and potentially fewer side effects, such as new-onset diabetes or medication intolerance Toth2022Lee2024. This approach is especially useful for patients who cannot tolerate high doses of statins.
Effectiveness in Older Adults
LDL cholesterol-lowering therapies, including both statins and nonstatin agents, are effective in reducing cardiovascular events in older adults (aged 75 and above), with benefits similar to those seen in younger patients .
Conclusion
Lowering LDL cholesterol is crucial for reducing cardiovascular risk. Statins remain the cornerstone of therapy, but a range of nonstatin and emerging agents are available for patients who need additional LDL reduction or cannot tolerate statins. Combination therapies and new drugs provide more options to achieve guideline-recommended LDL cholesterol targets for diverse patient populations Brautbar2011Nurmohamed2021Luo2022+7 MORE.
Sources and full results
Most relevant research papers on this topic